Eiko Lifescience

{
  "main_header": {
    "sid": 1002696,
    "name": "Eiko Lifescience",
    "stock_name": "Eiko Lifescience",
    "full_name": "Eiko Lifesciences Ltd",
    "name_url": "stocks-analysis/eiko-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "52.20",
    "chg": -0.8,
    "chgp": "-1.51%",
    "dir": -1,
    "prev_price": "53.00",
    "mcapval": "73.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540204,
    "symbol": "",
    "ind_name": "Specialty Chemicals",
    "ind_code": 5,
    "indexname": "",
    "isin": "INE666Q01016",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "20.15 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/eiko-lifescience-1002696-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Eiko Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-is-rated-sell-3817799",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EikoLifescience_mojoScore_3817799.png",
        "date": "2026-02-03 10:14:03",
        "description": "Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 February 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Eiko Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eiko-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-3813786",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EikoLifescience_valuationdot_3813786.png",
        "date": "2026-02-01 08:06:00",
        "description": "Eiko Lifesciences Ltd, a player in the Specialty Chemicals sector, has witnessed a notable improvement in its valuation attractiveness, shifting from very attractive to attractive. Despite a mixed performance against benchmark indices, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more compelling entry point for investors, even as its overall market sentiment remains cautious with a recent downgrade to a Sell rating."
      },
      {
        "title": "Why is Eiko Lifesciences Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-eiko-lifesciences-ltd-fallingrising-3812260",
        "imagepath": "",
        "date": "2026-01-31 00:55:24",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Context</strong></p>\n<p>Eiko Lifesciences has demonstrated notable resilience and strength in the short term, outperforming the broader market and its sector peers. Over the past week, the stock has delivered a remarkable 10.39% gain, substantially outpacing the Sensex’s modest 0.90% rise during the same period. This outperformance is particularly striking given the Sensex’s negative returns over the past month and year-to-date, which stand at -2.84% and -3.46% respectively. While the stock’s one-year return of 2.45% trails the Sensex’s 7.18%, its recent momentum signals renewed investor confidence.</p>\n<p><strong>Technical Indicators and Trading Activity</strong></p>\n<p>The stock’s technical positioning is robust, trading above all key moving averages inc..."
      },
      {
        "title": "Are Eiko Lifesciences Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-eiko-lifesciences-ltd-latest-results-good-or-bad-3810120",
        "imagepath": "",
        "date": "2026-01-29 19:24:35",
        "description": "Eiko Lifesciences Ltd's latest financial results for Q2 FY26 reflect a significant year-on-year growth in both net sales and net profit, indicating a robust operational performance. The company reported net sales of ₹11.67 crores, which represents a 43.01% increase compared to ₹8.16 crores in the same quarter last year. This growth is complemented by a substantial rise in net profit, which reached ₹1.08 crores, marking a remarkable 285.71% increase year-on-year. Additionally, the operating margin improved significantly to 15.17%, up from 5.15% in the previous year, showcasing enhanced operational efficiency.\n\nHowever, despite these positive metrics, the company faces challenges regarding its long-term financial health. The average return on equity (ROE) stands at a low 2.71%, raising concerns about capital efficiency and shareholder value creation. This weak ROE is notably below industry standards, suggesti..."
      },
      {
        "title": "Eiko Lifesciences Q2 FY26: Strong Profit Growth Masks Structural Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/eiko-lifesciences-q2-fy26-strong-profit-growth-masks-structural-concerns-3809953",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/EikoLifescience_quaterlyResult_3809953.png",
        "date": "2026-01-29 16:05:01",
        "description": "Eiko Lifesciences Ltd., a micro-cap speciality chemicals manufacturer, reported consolidated net profit of ₹1.08 crores for Q2 FY26, marking an impressive 285.71% year-on-year surge from ₹0.28 crores in Q2 FY25. However, despite the strong earnings momentum, the stock continues to languish, trading at ₹51.01 with a market capitalisation of just ₹71.00 crores, reflecting persistent investor scepticism about the company's long-term sustainability."
      },
      {
        "title": "Eiko Lifesciences Declines 9.99%: Bearish Signals and Downgrade Mark a Challenging Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eiko-lifesciences-declines-999-bearish-signals-and-downgrade-mark-a-challenging-week-3803314",
        "imagepath": "",
        "date": "2026-01-24 13:04:16",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Jan 21:</strong> Formation of Death Cross signalling potential bearish trend</p>\n                    <p><strong>Jan 21:</strong> Downgrade to Sell rating by MarketsMOJO</p>\n                    <p><strong>Jan 23:</strong> Week closes at Rs.49.28 (-9.99%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.53.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.49.28</div><div class=\"stat-change negative\">-9.99%</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\"..."
      },
      {
        "title": "Eiko Lifesciences Ltd Downgraded to Sell Amid Mixed Financials and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-downgraded-to-sell-amid-mixed-financials-and-bearish-technicals-3797842",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/EikoLifescience_mojoScore_3797842.png",
        "date": "2026-01-21 08:18:44",
        "description": "Eiko Lifesciences Ltd, a player in the Specialty Chemicals sector, has seen its investment rating downgraded from Hold to Sell as of 20 Jan 2026. This shift reflects a complex interplay of deteriorating technical indicators, mixed financial trends, valuation considerations, and overall quality assessments, signalling caution for investors despite recent positive quarterly results."
      },
      {
        "title": "Eiko Lifesciences Ltd Upgraded to Hold on Improved Technicals and Financial Performance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-upgraded-to-hold-on-improved-technicals-and-financial-performance-3791499",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/EikoLifescience_mojoScore_3791499.png",
        "date": "2026-01-14 08:17:46",
        "description": "Eiko Lifesciences Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and financial performance. The upgrade, effective from 13 January 2026, is underpinned by a combination of enhanced technical trends, robust quarterly earnings, attractive valuation metrics, and a stabilising financial trajectory, signalling cautious optimism for investors in the Specialty Chemicals sector."
      },
      {
        "title": "Eiko Lifesciences Ltd Downgraded to Sell Amid Mixed Financials and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-ltd-downgraded-to-sell-amid-mixed-financials-and-bearish-technicals-3786507",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/EikoLifescience_mojoScore_3786507.png",
        "date": "2026-01-09 08:16:02",
        "description": "Eiko Lifesciences Ltd, a player in the Specialty Chemicals sector, has seen its investment rating downgraded from Hold to Sell as of 8 January 2026. This shift reflects a complex interplay of deteriorating technical indicators, valuation attractiveness tempered by weak long-term fundamentals, and a mixed financial trend that has left investors cautious despite recent quarterly gains."
      }
    ],
    "total": 476,
    "sid": "1002696",
    "stock_news_url": "https://www.marketsmojo.com/news/eiko-lifesciences-1002696"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "30-Jan-2026",
      "details": "Newspaper publication of Un-audited Financial results (standalone & Consolidated) for Quarter and Nine- Months ended on 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Dated 29Th January 2026",
      "datetime": "29-Jan-2026",
      "details": "Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and amendments thereto this is to inform that the Meeting of the Board of Directors of the Company held today i.e. on Thursday 29th January 2026 Board inter-alia considered and approved Unaudited Financial Results (Standalone & Consolidated basis) for the Quarter ended 31st December 2025. The Statutory Auditors have carried out a Limited Review of the Unaudited Financial Results for the Quarter ended 31st December 2025. Further Pursuant to the Regulation 33 of the Listing Regulations we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company. The Meeting was commenced at 12: 30 PM and concluded at 13:00 PM.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Meeting Scheduled For Quarterly Results For The Quarter Ended 31St December 2025",
      "datetime": "16-Jan-2026",
      "details": "Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 inter alia to consider and approve Unaudited standalone and consolidated FInancial results for quarter ended 31st December 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Eiko Lifesciences Ltd has declared <strong>2%</strong> dividend, ex-date: 20 Sep 17",
          "dt": "2017-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Eiko Lifesciences Ltd has announced <strong>2:3</strong> rights issue, ex-date: 07 Jul 23",
          "dt": "2023-07-07",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Eiko Lifesciences Ltd is Rated Sell

2026-02-03 10:14:03

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Eiko Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-02-01 08:06:00

Eiko Lifesciences Ltd, a player in the Specialty Chemicals sector, has witnessed a notable improvement in its valuation attractiveness, shifting from very attractive to attractive. Despite a mixed performance against benchmark indices, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more compelling entry point for investors, even as its overall market sentiment remains cautious with a recent downgrade to a Sell rating.

Read full news article

Why is Eiko Lifesciences Ltd falling/rising?

2026-01-31 00:55:24

Recent Price Performance and Market Context

Eiko Lifesciences has demonstrated notable resilience and strength in the short term, outperforming the broader market and its sector peers. Over the past week, the stock has delivered a remarkable 10.39% gain, substantially outpacing the Sensex’s modest 0.90% rise during the same period. This outperformance is particularly striking given the Sensex’s negative returns over the past month and year-to-date, which stand at -2.84% and -3.46% respectively. While the stock’s one-year return of 2.45% trails the Sensex’s 7.18%, its recent momentum signals renewed investor confidence.

Technical Indicators and Trading Activity

The stock’s technical positioning is robust, trading above all key moving averages inc...

Read full news article

Are Eiko Lifesciences Ltd latest results good or bad?

2026-01-29 19:24:35

Eiko Lifesciences Ltd's latest financial results for Q2 FY26 reflect a significant year-on-year growth in both net sales and net profit, indicating a robust operational performance. The company reported net sales of ₹11.67 crores, which represents a 43.01% increase compared to ₹8.16 crores in the same quarter last year. This growth is complemented by a substantial rise in net profit, which reached ₹1.08 crores, marking a remarkable 285.71% increase year-on-year. Additionally, the operating margin improved significantly to 15.17%, up from 5.15% in the previous year, showcasing enhanced operational efficiency. However, despite these positive metrics, the company faces challenges regarding its long-term financial health. The average return on equity (ROE) stands at a low 2.71%, raising concerns about capital efficiency and shareholder value creation. This weak ROE is notably below industry standards, suggesti...

Read full news article

Eiko Lifesciences Q2 FY26: Strong Profit Growth Masks Structural Concerns

2026-01-29 16:05:01

Eiko Lifesciences Ltd., a micro-cap speciality chemicals manufacturer, reported consolidated net profit of ₹1.08 crores for Q2 FY26, marking an impressive 285.71% year-on-year surge from ₹0.28 crores in Q2 FY25. However, despite the strong earnings momentum, the stock continues to languish, trading at ₹51.01 with a market capitalisation of just ₹71.00 crores, reflecting persistent investor scepticism about the company's long-term sustainability.

Read full news article

Eiko Lifesciences Declines 9.99%: Bearish Signals and Downgrade Mark a Challenging Week

2026-01-24 13:04:16

Key Events This Week

Jan 21: Formation of Death Cross signalling potential bearish trend

Jan 21: Downgrade to Sell rating by MarketsMOJO

Jan 23: Week closes at Rs.49.28 (-9.99%)

Week Open

Rs.53.00

Week Close

Rs.49.28

-9.99%

Read full news article

Eiko Lifesciences Ltd Downgraded to Sell Amid Mixed Financials and Bearish Technicals

2026-01-21 08:18:44

Eiko Lifesciences Ltd, a player in the Specialty Chemicals sector, has seen its investment rating downgraded from Hold to Sell as of 20 Jan 2026. This shift reflects a complex interplay of deteriorating technical indicators, mixed financial trends, valuation considerations, and overall quality assessments, signalling caution for investors despite recent positive quarterly results.

Read full news article

Eiko Lifesciences Ltd Upgraded to Hold on Improved Technicals and Financial Performance

2026-01-14 08:17:46

Eiko Lifesciences Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and financial performance. The upgrade, effective from 13 January 2026, is underpinned by a combination of enhanced technical trends, robust quarterly earnings, attractive valuation metrics, and a stabilising financial trajectory, signalling cautious optimism for investors in the Specialty Chemicals sector.

Read full news article

Eiko Lifesciences Ltd Downgraded to Sell Amid Mixed Financials and Bearish Technicals

2026-01-09 08:16:02

Eiko Lifesciences Ltd, a player in the Specialty Chemicals sector, has seen its investment rating downgraded from Hold to Sell as of 8 January 2026. This shift reflects a complex interplay of deteriorating technical indicators, valuation attractiveness tempered by weak long-term fundamentals, and a mixed financial trend that has left investors cautious despite recent quarterly gains.

Read full news article

View All News